Trial Profile
A Prospective Trial of Neural Progenitor Cell Sparing Radiation Therapy Plus Temozolomide for Newly Diagnosed Glioblastoma Multiforme
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Jun 2019
Price :
$35
*
At a glance
- Drugs Temozolomide (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 23 May 2019 Status changed from active, no longer recruiting to completed.
- 04 Apr 2018 Planned End Date changed from 1 Jan 2018 to 1 Jan 2020.
- 04 Apr 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Jan 2020.